Giovana Seno Di Marco
University of Münster
Fibroblast growth factor 23Internal medicineCalcineurinEndocrinologyPathologyTyrosine hydroxylaseRenal functionCardiologyEnzymeChemistryRenin–angiotensin systemLeft ventricular hypertrophyKidney diseaseKidneyKidney transplantationBiochemistryFibroblast growth factor receptor 4MedicineFibroblast growth factorBiology
40Publications
18H-index
2,709Citations
Publications 40
Newest
Soluble Fms-like tyrosine kinase (sFlt-1/sVEGFR1) is a natural occurring antagonist of vascular endothelial growth factor (VEGF). Despite being a secreted, soluble protein lacking cytoplasmic and transmembrane domains, sFlt-1 can act locally and be protective against excessive microenvironmental VEGF concentration, or exert autocrine functions independently of VEGF. Circulating sFlt-1 may indiscriminately affect endothelial function and the microvasculature on distant target organs. The clinical...
Source
#1Bettina HesseH-Index: 3
#2Alexandros RovasH-Index: 6
Last. Alexander Lukasz (WWU: University of Münster)H-Index: 5
view all 12 authors...
Dysfunctional high-density lipoprotein (d-HDL) in chronic kidney disease is known to have a change in composition towards an endothelial-damaging phenotype, amongst others, via the accumulation of symmetric dimethylarginine. The endothelial glycocalyx, a carbohydrate-rich layer lining the endothelial luminal surface, is a first line defense against vascular diseases including atherosclerosis. Here we conducted a translational, cross-sectional study to determine the role of symmetric dimethylargi...
7 CitationsSource
#1Theresa M. WewersH-Index: 1
#2Anna B. MayerH-Index: 3
Last. Giovana Seno Di MarcoH-Index: 18
view all 12 authors...
Renal ischemia reperfusion injury (IRI) adversely affects clinical outcomes following kidney transplantation. Understanding the cellular mechanisms and the changes in gene/protein expression following IRI may help to improve these outcomes. Serum soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in the first week following kidney transplantation. We evaluated the casual relationship of elevated sFlt-1 levels with renal microvascular dysfunction follo...
6 CitationsSource
1 Citations
#1Lina GolleH-Index: 2
#2Hans Ulrich GerthH-Index: 11
Last. Marcus BrandH-Index: 15
view all 9 authors...
The reduced number of circulating stem/progenitor cells that is found in chronic kidney disease (CKD) patients may contribute to impaired angiogenic repair and decreased capillary density in the heart. Cell therapy with bone marrow-derived cells (BMDCs) has been shown to induce positive effects on the microvasculature and cardiac function, most likely due to secretion of growth factors and cytokines, all of which are present in the conditioned medium (CM); however, this is controversial. Here we...
17 CitationsSource
#1Alexander Grabner (UM: University of Miami)H-Index: 17
#2Karla Schramm (UM: University of Miami)H-Index: 5
Last. Christian Faul (UAB: University of Alabama at Birmingham)H-Index: 38
view all 14 authors...
Fibroblast growth factor (FGF) 23 is a phosphaturic hormone that directly targets cardiac myocytes via FGF receptor (FGFR) 4 thereby inducing hypertrophic myocyte growth and the development of left ventricular hypertrophy (LVH) in rodents. Serum FGF23 levels are highly elevated in patients with chronic kidney disease (CKD), and it is likely that FGF23 directly contributes to the high rates of LVH and cardiac death in CKD. It is currently unknown if the cardiac effects of FGF23 are solely patholo...
58 CitationsSource
#1Saurav Singh (UM: University of Miami)H-Index: 5
#2Alexander Grabner (UM: University of Miami)H-Index: 17
Last. Christian Faul (UM: University of Miami)H-Index: 38
view all 13 authors...
Patients with chronic kidney disease (CKD) develop increased levels of the phosphate-regulating hormone, fibroblast growth factor (FGF) 23, that are associated with a higher risk of mortality. Increases in inflammatory markers are another common feature that predicts poor clinical outcomes. Elevated FGF23 is associated with higher circulating levels of inflammatory cytokines in CKD, which can stimulate osteocyte production of FGF23. Here, we studied whether FGF23 can directly stimulate hepatic p...
195 CitationsSource
#1Lina GolleH-Index: 2
#2Katrin BeulH-Index: 2
Last. Marcus BrandH-Index: 15
view all 5 authors...
Source
#1Lina GolleH-Index: 2
#2Katrin BeulH-Index: 2
Last. Marcus BrandH-Index: 15
view all 5 authors...
Source
Chronisch nierenerkrankte Patienten leiden haufig unter einer Storung des Phosphathaushaltes. Mit zunehmendem Funktionsverlust der Niere kommt es zu einer Phosphatretention und einem progredienten Anstieg des Fibroblasten-Wachstums-Faktor-23 (FGF-23), einem Hormon, das den Serum-Phosphat-Haushalt reguliert. Erhohte Serum-Phosphat- und FGF-23-Spiegel sind mit einem erhohten Risiko fur die Gesamtsterblichkeit und dem Auftreten kardiovaskularer Ereignisse assoziiert. Interessanterweise besteht eine...
Source